STERIS (NYSE:STE) Posts Earnings Results, Beats Estimates By $0.03 EPS

STERIS (NYSE:STE) posted its quarterly earnings results on Wednesday. The medical equipment provider reported $2.14 EPS for the quarter, topping the consensus estimate of $2.11 by $0.03, Briefing.com reports. The company had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.91%. The firm’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.03 EPS. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Stock Up 0.9 %

NYSE STE traded up $1.87 on Friday, hitting $217.37. The stock had a trading volume of 498,076 shares, compared to its average volume of 487,954. The business’s fifty day moving average price is $232.73 and its 200 day moving average price is $227.52. The stock has a market cap of $21.44 billion, a price-to-earnings ratio of 49.20 and a beta of 0.85. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49. STERIS has a 52-week low of $195.47 and a 52-week high of $248.24.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be paid a $0.57 dividend. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 annualized dividend and a yield of 1.05%. STERIS’s dividend payout ratio (DPR) is 52.05%.

Insider Transactions at STERIS

In related news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on STE shares. Stephens reaffirmed an “overweight” rating and set a $260.00 price target on shares of STERIS in a research note on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Friday. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. KeyCorp upped their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Finally, JMP Securities reissued a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, STERIS currently has a consensus rating of “Moderate Buy” and an average price target of $253.00.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.